Published on
00:05 GMT
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
Positive results from the phase 2 AUGMENT-101 trial showed that revumenib (SNDX-5613), an oral Menin inhibitor, achieved a 23% complete remission (CR) or CR with partial blood count recovery rate (CRh; 15/64; 95% CI, 14%-36%; P =.0014) in efficacy- …
Source:
Targeted Oncology
-
Label Pending
